eTheRNA
PrivateLast Round
Series B
Extension
Aug 23, 2022
Total Funding Raised
$103.6M
Company Overview
eTheRNA operates in Healthcare & Life Sciences and is based in Niel. Its latest recorded funding round was a Series B Extension round in August 2022.
eTheRNA is a biotechnology company that provides mRNA and lipid nanoparticle (LNP) technology platforms for the development and manufacturing of RNA-based therapeutics.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
eTheRNA Comparables
Compare eTheRNA with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Acuitas Therapeutics | 86% | |
| Genevant Sciences | 84% | |
| Pantherna Therapeutics | 83% |
For institutional investors. Book with your work email.
eTheRNA Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Aug 23, 2022 | ||||
| Series B | Jun 16, 2020 | ||||
| Series A | Mar 17, 2016 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
eTheRNA Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Yijing Capital | Series B |
| Omega Funds | Series B Extension, Series A, Series B |
| EQT Life Sciences | Series B Extension, Series B, Series A |
| Fund+ | Series B Extension, Series A, Series B |
| Novalis LifeSciences | Series B Extension, Series B |
| PMV | Series B Extension, Series B, Series A |
| Yijing Capital | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 16, 2026
Monthly visitors grew 48% MoM, reaching 7.8K.
- Aug 23, 2022
$39M round led by Novalis LifeSciences.
For institutional investors. Book with your work email.
eTheRNA Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about eTheRNA's valuation, stock price, and market status.
Is eTheRNA a public or private company?
eTheRNA is a private company.
What is the current stock price of eTheRNA?
eTheRNA is a private company, so its shares have no public market price. Caplight tracks eTheRNA's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is eTheRNA worth (valuation)?
Valuation information for eTheRNA is not publicly available.
Can I buy eTheRNA stock?
eTheRNA shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was eTheRNA's last funding round?
eTheRNA's most recent funding round was Series B Extension on August 23, 2022.
Who are the main investors in eTheRNA?
Key investors in eTheRNA include EQT Life Sciences, Novalis LifeSciences, PMV, BNP Paribas Fortis.
Will eTheRNA IPO soon?
No public IPO plans have been announced for eTheRNA.
How can I track eTheRNA secondary market activity?
Caplight tracks bids, offers, and trades in eTheRNA's shares on secondary markets.